Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133489) titled 'HER2 PET-CT Predicts the Efficacy and Prognosis of Disitamab Vedotin in Treating HER2-Positive Metastatic Urothelial Carcinoma' on Sept. 28.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Huashan Hospital, Fudan University
Condition:
HER2-positive locally advanced/metastatic urothelial carcinoma
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-02
Target Sample Size: experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=338888
Disclaimer: Curated by HT Syndication....